• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Asarina Pharma

Less than 1K followers
All
Press releases
ShowingAll content types

Regulatory press release16.09.2024 klo 21.00

Asarina Pharma AB (publ) shares to be delisted and the last day of trading is 1 October 2024

Asarina Pharma
Regulatory press release13.09.2024 klo 12.00

Asarina Pharma applies for the delisting of the company's shares

Asarina Pharma
Regulatory press release21.08.2024 klo 12.30

Bulletin from the extraordinary general meeting and first control meeting in Asarina Pharma

Asarina Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release22.07.2024 klo 09.00

NOTICE OF EXTRAORDINARY GENERAL MEETING AND FIRST CONTROL MEETING IN ASARINA PHARMA AB (PUBL)

Asarina Pharma
Regulatory press release18.07.2024 klo 18.45

ASARINA PHARMA ANNOUNCES OUTCOME OF PARTNERING PROCESS, CONTROL BALANCE SHEET AND PROPOSAL TO LIQUIDATE

Asarina Pharma
Regulatory press release27.06.2024 klo 12.33

Bulletin from the Annual General Meeting of Asarina Pharma AB (publ)

Asarina Pharma
Regulatory press release04.06.2024 klo 23.54

ASARINA PHARMA AB (PUBL) RELEASES ANNUAL REPORT 2023

Asarina Pharma
Regulatory press release28.05.2024 klo 23.00

Asarina Pharma AB announces new date for the release of Annual Report for 2023

Asarina Pharma
Regulatory press release21.05.2024 klo 12.50

Asarina Pharma AB announces new date for the release of Annual Report for 2023

Asarina Pharma
Regulatory press release27.02.2024 klo 09.30

ASARINA PHARMA AB (PUBL) RELEASES YEAR-END REPORT 2023

Asarina Pharma
Regulatory press release30.11.2023 klo 11.30

Asarina Pharma AB changes Certified Adviser to Carnegie Investment Bank AB

Asarina Pharma
Regulatory press release16.11.2023 klo 09.33

Asarina Pharma updates on partnering and financials

Asarina Pharma
Regulatory press release23.08.2023 klo 09.30

Asarina Pharma AB (publ) releases First Half-Year Report (H1/2023)

Asarina Pharma
Regulatory press release23.05.2023 klo 10.02

Positive Tourette Syndrome results to be presented at ESSTS, 15th European Conference on Tourette Syndrome and Tic Disorders

Asarina Pharma
Regulatory press release22.05.2023 klo 12.15

Bulletin from the Annual General Meeting of Asarina Pharma AB (publ)

Asarina Pharma
Regulatory press release05.05.2023 klo 14.33

Asarina Pharma's positive Phase IIa Tourette Syndrome results to be presented at TicCon, the Virtual National Conference of the Tourette Association of America

Asarina Pharma
Regulatory press release28.04.2023 klo 21.30

Asarina Pharma AB (publ) releases Annual Report 2022

Asarina Pharma
Regulatory press release18.04.2023 klo 11.39

Asarina Pharma: NOTICE OF ANNUAL GENERAL MEETING IN ASARINA PHARMA AB (PUBL)

Asarina Pharma
Regulatory press release01.04.2023 klo 15.20

Asarina Pharma publishes positive results from its Phase IIa study of Sepranolone in Tourette Syndrome

Asarina Pharma
Regulatory press release27.02.2023 klo 09.30

Asarina Pharma AB (publ) releases Year-End Report 2022

Asarina Pharma